Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Middle East Conflict Impacts Australia and New Zealand Businesses 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
REDWOOD CITY, Calif., May 01, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:40 am ET being held in Las Vegas, Nevada.
The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
